WO2007060381A1 - Préparations contenant du strontium et leur application à des méthodes de traitement cosmétique - Google Patents

Préparations contenant du strontium et leur application à des méthodes de traitement cosmétique Download PDF

Info

Publication number
WO2007060381A1
WO2007060381A1 PCT/GB2006/001138 GB2006001138W WO2007060381A1 WO 2007060381 A1 WO2007060381 A1 WO 2007060381A1 GB 2006001138 W GB2006001138 W GB 2006001138W WO 2007060381 A1 WO2007060381 A1 WO 2007060381A1
Authority
WO
WIPO (PCT)
Prior art keywords
strontium
skin
weight
cosmetic
products
Prior art date
Application number
PCT/GB2006/001138
Other languages
English (en)
Inventor
Jo Klaveness
Thorfinn Ege
Original Assignee
Santosolve As
Golding, Louise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20055564A external-priority patent/NO20055564L/no
Application filed by Santosolve As, Golding, Louise filed Critical Santosolve As
Publication of WO2007060381A1 publication Critical patent/WO2007060381A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to novel strontium-containing compositions and their use in methods of cosmetic treatment.
  • Strontium compounds are known for topical use in the reduction of skin irritation.
  • both WO 97/48371 and WO 96/19184 (Cosmederm) describe topical formulations containing strontium for preventing, reducing or eliminating the potential irritation caused by topical application of products containing irritating agents, especially cosmetic products containing hydroxy acids or other exfoliating agents.
  • the divalent strontium cation is provided at a concentration which is effective to reduce irritation to the skin.
  • concentrations of strontium salts that provide an optimum consumer benefit in terms of anti-irritant properties are approx. 4 to 6% by weight (approx. 190 to 28OmM).
  • Strontium nitrate is the preferred choice of anti-irritant agent and is generally used at a concentration of 250 niM (5.7% by weight).
  • US-A-5,866,168 (L'Oreal) describes dermatological/pharmaceutical compositions comprising at least one lanthanide, manganese, tin, zinc, yttrium, cobalt, barium or strontium salt as a substance P antagonist.
  • Such compositions are intended for use in the medical treatment and/or alleviation of pain associated with certain skin disorders, including skin ulcers, hypertrophic cicatrization and acne rosacea.
  • strontium compounds have been proposed for use in other methods of medical treatment.
  • the use of strontium compounds to treat sub-dermal soft tissue pain is described in WO 03/028742 (Santosolve).
  • WO 04/849920 (Santosolve) relates to strontium compounds for inflammatory treatment.
  • compositions containing certain strontium compounds in low concentrations are effective to enhance the cosmetic appearance and/or the personal well-being of a subject, preferably a human subject, when topically applied to the body.
  • the invention provides a cosmetic formulation comprising strontium in an amount of up to 2.5% by weight, together with a physiologically acceptable carrier or excipient, wherein the strontium is present in the form of strontium chloride, strontium acetate or a hydrate thereof.
  • the invention provides a method of cosmetic treatment of a human or non-human subject, preferably a human subject, said method comprising topically applying to said subject a composition comprising strontium in an amount of up to 2.5% by weight, wherein the strontium is present in the form of strontium chloride, strontium acetate or a hydrate thereof.
  • the invention provides the use as a cosmetic preparation of a composition comprising strontium in an amount of up to 2.5% by weight, wherein the strontium is present in the form of strontium chloride, strontium acetate or a hydrate thereof.
  • Cosmetic treatment in relation to any product or method of treatment is intended to define a product or treatment which is used or intended for use solely for cosmetic purposes, i.e. to enhance or maintain the cosmetic appearance and/or the personal welfare of a human or non-human subject.
  • Cosmetic treatment includes any method which serves (i) to maintain or alter (e.g. enhance) a subject's appearance; (ii) to protect a subject from environmental conditions such as sunlight, wind, extremes in temperature and/or humidity, etc.; or (iii) to produce a biological change in the subject's skin for cosmetic purposes.
  • Cosmetic treatment specifically excludes any method of medical treatment of a subject, in particular any method for treating or alleviating the symptoms of a disease.
  • compositions herein described may be employed to impart a pleasant or comfortable feeling (e.g. a soothing and/or calming effect) to the skin following topical application, e.g. on application to the skin's surface.
  • a pleasant or comfortable feeling e.g. a soothing and/or calming effect
  • these may provide effective relief to hypersensitive or sensitized skins.
  • skins may be generally described as "uncomfortable” or, more specifically, may be associated with one or more of the following symptoms: discomfort, stinging, burning, itching and tightness.
  • the compositions according to the invention may also be used to provide effective relief to skin either prior to, during or following exposure to harsh weather conditions, such as wind, cold, sun, humidity, etc.
  • compositions according to the invention comprise strontium in the form of strontium chloride, strontium acetate or a hydrate thereof. Mixtures of any of these compounds may also be employed.
  • strontium chloride is strontium chloride. Particularly preferably, this may be used in the form of strontium chloride hexahydrate.
  • the concentration of strontium in the compositions according to the invention will typically be up to about 2.1% by weight (w/w calculated as strontium), preferably in the range 0.5 to 2.1% by weight, more preferably 0.7 to 2.0% by weight, e.g. 1.0 to 2.0% by weight.
  • strontium compounds herein described may be dissolved or dispersed in any appropriate vehicle, e.g. a physiologically acceptable carrier or excipient such as those described herein. Preferred carriers and excipients are those which are non- irritating to the skin.
  • a physiologically acceptable carrier or excipient such as those described herein.
  • Preferred carriers and excipients are those which are non- irritating to the skin.
  • the strontium compounds herein described may be employed as the sole active component of a cosmetic formulation, preferably these will be used in a conventional cosmetic formulation in order to further enhance the cosmetic properties of the product. Examples of such products which contain safe (i.e. non-irritating) cosmetics to which the strontium compounds may be added include the following:
  • Vaseline ® Intensive Care Extra Strength Body Lotion contains: water, glycerin, petrolatum, paraffinum liquidum, stearic acid, glycol stearate, stearamide AMP, cetyl acetate, acetylated lanolin alcohol, glyceryl stearate, triethanolamine, dimethicone, magnesium aluminum silicate, PEG-40 stearate, cetyl alcohol, perfume, methylparaben, propylparaben, carbomer, disodium EDTA, DMDM and hydantoin.
  • Natusan Baby Lotion (Johnson & Johnson, Dusseldorf, SCA Hygiene Products AS, T ⁇ nsberg, Norway) contains: water, paraffinum liquidum, petrolatum, Elaeis Guineensis oil, lanolin, glycerin, glycine soya oil, helianthus annusus seed oil, dimethicone, cetyl alcohol, stearyl alcohol, acrylates/C lo-3 o alkyl acrylate crosspolymer, carbomer, sodium hydroxide, phenoxyethanol, methylparaben, propylparaben and perfume.
  • Wella Balsam Shampoo (Wella AS, Darmstadt, Germany) contains: water, cetearyl alcohol, cetrimonium chloride, dimethicone, phenoxyethanol, perfume, isopropyl alcohol, methylparaben, CL 77891, buxus chinensis, citrus dulcis and pyrus malus.
  • Natusan ® pH 5.5 Shampoo contains: water, ammonium lauryl sulphate, ammonium laureth sulphate, cocamidopropyl betaine, glycol distearate, lauramide MEA, methylparaben, tetrasodium EDTA, sodium benzoate, guar hydroxypropyltrimonium chloride, BHT, silicone, guanternium-13, acrylamidopropyltrimonium chloride/acrylamide copolymer, panthenol, PEG-14M, PEG-4, wheat amino acids, phytantriol, citric acid, iodopropynyl butylcarbamate, propylene glycol, quaternium-80, sodium chloride, polysorbate 20, PEG-4 laurate, PEG-4 dilaurate and perfume.
  • Vaseline ® Intensive Care Mild shower Gel contains: water, sodium laureth sulfate, glycerin, cocamidopropyl betaine, glycol distearate, perfume, lanolin alcohol, stearic acid, PPG-9, acrylates/Qo-so alkyl acrylate crosspolymer, guar hydroxypropyltrimonium chloride, PEG-40 hydrogenated castor oil, laureth-4, aloe barbadensis, potassium sorbate, sodium benzoate, tocopheryl acetate, citric acid, sodium hydroxide and sodium chloride.
  • the cosmetic products mentioned above contain certain components that might be regarded as skin irritants when used at high concentrations. However, in the products listed, these are not present in an amount sufficient to irritate the skin.
  • the strontium compounds herein described are not intended for use in preventing or reducing the irritation which may be associated with any conventional cosmetic products. Where any potentially skin irritating components are present in the formulations according to the invention, these will generally be present in sufficiently low concentrations that these do not irritate the skin. Such concentrations will depend on the nature of the skin irritant but typically will be of the order of less than 5% by weight, preferably less than 3% by weight, e.g. less than 2% by weight. Most preferably, the compositions of the invention will be substantially free from any skin irritating components. For example, any such components will be present in an amount of less than 1% by weight, e.g. less than 0.5% by weight.
  • skin irritating component and “skin irritant” are used interchangeably to define any compound which when topically applied to a human or non-human subject (e.g. when applied to the surface of the skin) at a given concentration will irritate the skin.
  • Symptoms of skin irritation may include itching (pruritus), inflammation, stinging, burning, tightness of the skin, erythema or oedema.
  • Skin irritants may include not only components of cosmetic products which may be considered inert, e.g. fragrances, preservatives, solvents, etc., but also active components of the products such as exfoliants and skin cell renewal agents, anti-perspirant compounds, skin protective agents, chemical sunscreen agents, etc.
  • Known skin irritants include, for example, those compounds conventionally used as exfoliants and/or cell renewal agents to reduce the occurrence or severity of skin wrinkles, and anti-acne agents.
  • Such compounds include carboxylic acids such as alpha-hydroxy acids (e.g. lactic acid, glycolic acid), beta-hydroxy acids (e.g. salicylic acid); retinoids (e.g. tretinoin, retinol); peroxides (e.g. benzoyl peroxide); and organic alcohols.
  • the strontium compounds herein described are not provided in any conventional anti-aging or anti-wrinkle product, e.g. one containing alpha-hydroxy acids, beta-hydroxy acids or a retinoid.
  • the compositions in accordance with the invention will thus be substantially free from any anti-aging or anti-wrinkle agents.
  • these will contain less than 1% by weight, preferably less than 0.1% by weight, more preferably less than 0.01% by weight, of any anti-aging or anti-wrinkle agent such as an alpha-hydroxy acid, beta-hydroxy acid or retinoid.
  • acetyl choline and its salts - spironolactone methotrexate aminocapric acid chinophen and its salts or derivatives trichloro-acetic acid - epinephrine rauwolf ⁇ a serpentia (in any form) alkyne alcohols allyl isothicyanate nalorphine - aniline procainamide benzidine
  • 4-tert-butylphenol dioxane chloroform coal tar Included in this listing of compounds are salts, esters and other derivatives which form any of the above-mentioned compounds in vivo.
  • compositions according to the invention will be substantially free from any of the above-mentioned compounds, for example these will be present in an amount of less than 1% by weight, more preferably less than 0.1% by weight, e.g. less than 0.01 % by weight.
  • formulations herein described will generally be prepared by simple mixing of an appropriate amount of the chosen strontium compound into the chosen formulation vehicle, optionally together with any cosmetic components as are desired.
  • suitable topical vehicles and vehicle components for use with the formulations according to the invention are well known in the field of cosmetics and include such vehicles as solvents (e.g.
  • lipid-based materials such as fatty acids, acylglycerols, phosphoglycerides
  • protein-based materials such as collagen and gelatin
  • silicone-based materials such as cyclomethicone, dimethicone
  • hydrocarbon-based materials such as petrolatum and squalene
  • anionic, cationic and amphoteric surfactants and soaps sustained release vehicles such as microsponges and polymer matrices; stabilizing and suspending agents; and emulsifying agents.
  • Other components may be provided to improve the stability or effectiveness of the formulations such as preservatives, redox agents (e.g.
  • antioxidants include perfumes, sunscreens, odour absorbers and colourants.
  • the amounts of these various adjuvants and additives are those conventionally used in the cosmetic field and may range, for example, from 0.01 to 20% of the total weight of the formulation.
  • compositions according to the invention may be used as cosmetic preparations, in particular as skin and hair products.
  • these will be topically applied to the body of a human or non-human animal, preferably to a human.
  • these may be administered directly onto the skin's surface (on any area of the skin), onto the hair (wet or dry hair) and/or onto the nails.
  • compositions may be provided in a variety of forms, including solids (e.g. soaps or cleansing bars), liquids, emulsions, semi-solids (e.g. creams, gels, lotions or pastes), powders or aerosols.
  • solids e.g. soaps or cleansing bars
  • liquids e.g. soaps or cleansing bars
  • emulsions e.g. creams, gels, lotions or pastes
  • powders or aerosols e.g. creams, gels, lotions or pastes
  • these may be provided in the form of a high viscosity fluid, e.g. a gel.
  • topical products used as cosmetics and to which the strontium compounds herein described may be added include skin care products such as moisturising creams and lotions, skin cleansers and toners, exfoliants and skin cell renewal agents, anti-wrinkle products; fragrances such as perfumes, deodorants and anti-perspirants; shaving products such as shaving creams and after-shaves; depilatories and other hair removal products; sunbathing products such as tanning lotions, sunscreens, sunblocks and after-sun products; artificial tanning products; skin-whitening products; cleansing products such as toilet soaps and gels; bath products such as bath and shower compositions, after-bath compositions; eye care products such as eye lotions and make-up removers; make-up products such as foundations, blushers, eye shadows and eye liners, lipsticks, mascaras, powders; products for application to the lips such as lip balms and sticks; hair care and treatment products such as shampoos, conditioners, colourants, dyes, bleaches, permanent- wa
  • the strontium compounds are effective to impart a pleasant (e.g. soothing and/or calming) effect on the skin, hair or nails, especially on the skin.
  • the strontium compounds herein described may be used in an after-sun product where these are effective in soothing or calming the skin following exposure to the sun.
  • Strontium chloride hexahydrate (6.05 g) was mixed into Vaseline Intensive Care Extra Strength Body Lotion (Lilleborg AS, Oslo, Norway) (94g) using a mortar and pestle. The lotion was filled into a plastic vial.
  • the lotion contained 2% (w/w) strontium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des formules cosmétiques comprenant du strontium à une teneur pouvant aller jusqu'à 2,5 % en masse, préférentiellement jusqu'à 2,1 % en masse, combiné à un vecteur ou un excipient de qualité physiologique, le strontium étant présent sous forme de chlorure de strontium, d'acétate de strontium ou d'un hydrate de ces substances. De telles formules peuvent être employées afin d'améliorer l'apparence cosmétique et/ou le bien-être personnel d'un sujet, préférentiellement un sujet humain, lorsqu'elles sont appliquées de façon locale sur le corps.
PCT/GB2006/001138 2005-11-24 2006-03-29 Préparations contenant du strontium et leur application à des méthodes de traitement cosmétique WO2007060381A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20055564A NO20055564L (no) 2005-03-24 2005-11-24 Strontium IV
NO20055564 2005-11-24

Publications (1)

Publication Number Publication Date
WO2007060381A1 true WO2007060381A1 (fr) 2007-05-31

Family

ID=36589163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001138 WO2007060381A1 (fr) 2005-11-24 2006-03-29 Préparations contenant du strontium et leur application à des méthodes de traitement cosmétique

Country Status (1)

Country Link
WO (1) WO2007060381A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111195259A (zh) * 2018-11-16 2020-05-26 深圳市阳光百度生物科技发展有限公司 一种氯化锶与d-泛醇复合制剂的制备方法及其抗敏修复的应用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346957A1 (fr) * 1988-05-19 1989-12-20 Unilever N.V. Compositions orales
US4978522A (en) * 1987-10-06 1990-12-18 The Procter & Gamble Company Oral compositions
WO1993025183A1 (fr) * 1992-06-16 1993-12-23 Smithkline Beecham Plc Collutoire pour traiter l'hypersensibilite de la dentine
FR2732603A1 (fr) * 1995-04-10 1996-10-11 Oreal Utilisation d'un sel de strontium comme antagoniste de substance p
FR2732601A1 (fr) * 1995-04-10 1996-10-11 Oreal Utilisation d'un sel de metal alcalino-terreux pour le traitement des rougeurs cutanees d'origine neurogene
US5851556A (en) * 1995-04-10 1998-12-22 Societe L'oreal S.A. Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained
US5922764A (en) * 1996-01-23 1999-07-13 L'oreal Stable gelled composition with a high electrolyte content
US6331307B1 (en) * 1996-10-11 2001-12-18 L'oreal O/W emulsion with a high electrolyte content and its use in dermocosmetics, in particular for treating irritation and/or sensitive skin phenomena
US20030124202A1 (en) * 1994-12-21 2003-07-03 Hahn Gary S. Formulations and methods for reducing skin irritation
WO2004004645A2 (fr) * 2002-07-10 2004-01-15 Armkell Llc. Composition permettant de diminuer les mauvaises odeurs lors d'un traitement capillaire et d'une epilation, et methode d'utilisation de cette composition
EP1419760A1 (fr) * 2002-11-12 2004-05-19 Reheis, Inc. compositions antitranspirantes à éfficacité améliorée contenant du strontium
EP1593371A1 (fr) * 2004-05-05 2005-11-09 Sara Lee/DE N.V. Compositions de soin corporel contenant des tampons acides

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978522A (en) * 1987-10-06 1990-12-18 The Procter & Gamble Company Oral compositions
EP0346957A1 (fr) * 1988-05-19 1989-12-20 Unilever N.V. Compositions orales
WO1993025183A1 (fr) * 1992-06-16 1993-12-23 Smithkline Beecham Plc Collutoire pour traiter l'hypersensibilite de la dentine
US20030124202A1 (en) * 1994-12-21 2003-07-03 Hahn Gary S. Formulations and methods for reducing skin irritation
FR2732603A1 (fr) * 1995-04-10 1996-10-11 Oreal Utilisation d'un sel de strontium comme antagoniste de substance p
FR2732601A1 (fr) * 1995-04-10 1996-10-11 Oreal Utilisation d'un sel de metal alcalino-terreux pour le traitement des rougeurs cutanees d'origine neurogene
US5851556A (en) * 1995-04-10 1998-12-22 Societe L'oreal S.A. Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained
US5922764A (en) * 1996-01-23 1999-07-13 L'oreal Stable gelled composition with a high electrolyte content
US6331307B1 (en) * 1996-10-11 2001-12-18 L'oreal O/W emulsion with a high electrolyte content and its use in dermocosmetics, in particular for treating irritation and/or sensitive skin phenomena
WO2004004645A2 (fr) * 2002-07-10 2004-01-15 Armkell Llc. Composition permettant de diminuer les mauvaises odeurs lors d'un traitement capillaire et d'une epilation, et methode d'utilisation de cette composition
EP1419760A1 (fr) * 2002-11-12 2004-05-19 Reheis, Inc. compositions antitranspirantes à éfficacité améliorée contenant du strontium
EP1593371A1 (fr) * 2004-05-05 2005-11-09 Sara Lee/DE N.V. Compositions de soin corporel contenant des tampons acides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111195259A (zh) * 2018-11-16 2020-05-26 深圳市阳光百度生物科技发展有限公司 一种氯化锶与d-泛醇复合制剂的制备方法及其抗敏修复的应用

Similar Documents

Publication Publication Date Title
US5621008A (en) N-acyl-ethylene-triacetic acids
JP2885808B2 (ja) ソルビン酸トコフェロールと抗炎症剤を含む光保護組成物
CA2188892C (fr) Utilisation d'un sel d'yttrium dans une composition destinee au traitement des peaux sensibles
CA2866527C (fr) Utilisation d'esters d'isoeugenol pour le traitement de l'hyperpigmentation
US10869822B2 (en) Compositions for treatment of dermatological diseases and conditions and methods of use thereof
US9399030B2 (en) Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same
WO1996023490A1 (fr) Formulations et procedes permettant de reduire l'irritation cutanee
WO1996023490A9 (fr) Formulations et procedes permettant de reduire l'irritation cutanee
US6540987B2 (en) Polyesters based on hydroxy fatty acids and lower hydroxy alkyl acids and uses thereof
EP1294351A1 (fr) Utilisation de substances liberant ou liant le calcium pour diminuer ou renforcer de maniere ciblee la fonction de barriere de la peau
US20080262095A1 (en) Protectant for UV-Induced Skin Damage
US11918666B2 (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
JPH10167957A (ja) 細胞間接着抑制剤
WO2007060381A1 (fr) Préparations contenant du strontium et leur application à des méthodes de traitement cosmétique
US20060148907A1 (en) Topical antinflammatory preparations of y-terpinene
JPH08104635A (ja) フィチン酸亜鉛を有効成分とする外用製剤
GB2425060A (en) Strontium compounds in cosmetics
FR2968952A1 (fr) Ester d'acide amine n-acyle a titre d'agent apaisant
EP4327824A1 (fr) Composition topique comprenant du chlore e6 et du du l-pyroglutamate de zinc
JPH11286442A (ja) 炎症因子活性化抑制剤
WO2011001165A2 (fr) Formulations
JPH01207217A (ja) 皮膚化粧料
AU1803302A (en) Topical anti-inflammatory preparations
JP2004307347A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06726547

Country of ref document: EP

Kind code of ref document: A1